NASDAQ:AMPH Amphastar Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $34.15 +0.90 (+2.71%) (As of 06/29/2022 12:00 AM ET) Add Compare Share Today's Range$32.54▼$34.4950-Day Range$29.79▼$41.4152-Week Range$17.56▼$44.46Volume331,829 shsAverage Volume506,361 shsMarket Capitalization$1.67 billionP/E Ratio21.21Dividend YieldN/APrice Target$36.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMPH Stock Forecast (MarketRank)Overall MarketRank™2.46 out of 5 starsMedical Sector74th out of 1,432 stocksPharmaceutical Preparations Industry26th out of 685 stocksAnalyst Opinion: 1.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 3.1 5 -4 -3 -2 -1 - 1.3 Analyst's Opinion Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.67, Amphastar Pharmaceuticals has a forecasted upside of 7.4% from its current price of $34.15.Amount of Analyst CoverageAmphastar Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 4.5 Community Rank Outperform VotesAmphastar Pharmaceuticals has received 365 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAmphastar Pharmaceuticals has received 173 “underperform” votes. (Add your “underperform” vote.)Community SentimentAmphastar Pharmaceuticals has received 67.84% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote “Outperform” if you believe AMPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AMPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAmphastar Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmphastar Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,965,329.00 in company stock.Percentage Held by Insiders27.80% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions59.79% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Amphastar Pharmaceuticals are expected to grow by 17.12% in the coming year, from $1.46 to $1.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amphastar Pharmaceuticals is 21.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.23.Price to Earnings Ratio vs. SectorThe P/E ratio of Amphastar Pharmaceuticals is 21.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.28.Price to Book Value per Share RatioAmphastar Pharmaceuticals has a P/B Ratio of 3.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amphastar Pharmaceuticals (NASDAQ:AMPH)Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Read More AMPH Stock News HeadlinesJune 29, 2022 | americanbankingnews.comAmphastar Pharmaceuticals (NASDAQ:AMPH) Trading 5.9% Higher June 28, 2022 | finance.yahoo.comAmphastar Pharmaceuticals' (NASDAQ:AMPH) five-year earnings growth trails the 14% YoY shareholder returnsJune 24, 2022 | americanbankingnews.comWilliam J. Peters Sells 5,512 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) StockJune 13, 2022 | benzinga.comAmphastar Pharmaceuticals (NASDAQ:AMPH), Short Interest ReportJune 9, 2022 | americanbankingnews.comHoward Lee Sells 10,291 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) StockJune 9, 2022 | americanbankingnews.comAmphastar Pharmaceuticals (NASDAQ:AMPH) Trading Down 6.5% on Insider SellingJune 7, 2022 | finance.yahoo.comDow Jones, Nasdaq Finish Higher After Weak Opening; Growth Stocks Outperform While Oil Plays Near Buy PointsJune 6, 2022 | finanznachrichten.deAmphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Jefferies Healthcare ConferenceJune 6, 2022 | finance.yahoo.comAmphastar Pharmaceuticals to Present at the Jefferies Healthcare ConferenceJune 2, 2022 | finance.yahoo.comIBD 50 Stocks To Watch: Why Top Biotech Stock Amphastar Deserves Closer LookMay 30, 2022 | finance.yahoo.comWe Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With EaseMay 26, 2022 | nasdaq.comFirst Week of July 15th Options Trading For Amphastar Pharmaceuticals (AMPH)May 26, 2022 | finanznachrichten.deAmphastar Pharmaceuticals, Inc.: Amphastar Receives FDA Approval for RegadenosonSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AMPH CUSIPN/A CIK1297184 Webwww.amphastar.com Phone(909) 980-9484Fax909-980-8296Employees1,761Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today6/29/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$36.67 High Stock Price Forecast$43.00 Low Stock Price Forecast$32.00 Forecasted Upside/Downside+7.4%Consensus RatingModerate Buy Rating Score (0-4)2.66666666666667 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$1.61 Trailing P/E Ratio21.21 Forward P/E Ratio23.39 P/E GrowthN/ANet Income$62.12 million Net Margins17.87% Pretax Margin23.74% Return on Equity17.35% Return on Assets11.69% Debt Debt-to-Equity Ratio0.16 Current Ratio3.19 Quick Ratio2.35 Sales & Book Value Annual Sales$437.77 million Price / Sales3.81 Cash Flow$2.05 per share Price / Cash Flow16.62 Book Value$9.31 per share Price / Book3.67Miscellaneous Outstanding Shares48,830,000Free Float35,255,000Market Cap$1.67 billion OptionableOptionable Beta0.65 Amphastar Pharmaceuticals Frequently Asked Questions Should I buy or sell Amphastar Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Amphastar Pharmaceuticals stock. View analyst ratings for Amphastar Pharmaceuticals or view top-rated stocks. What is Amphastar Pharmaceuticals' stock price forecast for 2022? 3 Wall Street analysts have issued 1-year price objectives for Amphastar Pharmaceuticals' stock. Their AMPH stock forecasts range from $32.00 to $43.00. On average, they predict Amphastar Pharmaceuticals' stock price to reach $36.67 in the next twelve months. This suggests a possible upside of 7.4% from the stock's current price. View analysts' price targets for Amphastar Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Amphastar Pharmaceuticals' stock performed in 2022? Amphastar Pharmaceuticals' stock was trading at $23.29 on January 1st, 2022. Since then, AMPH shares have increased by 46.6% and is now trading at $34.15. View the best growth stocks for 2022 here. When is Amphastar Pharmaceuticals' next earnings date? Amphastar Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Amphastar Pharmaceuticals. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its quarterly earnings data on Monday, May, 9th. The company reported $0.47 earnings per share for the quarter, topping analysts' consensus estimates of $0.33 by $0.14. The company had revenue of $120.37 million for the quarter, compared to the consensus estimate of $110.60 million. Amphastar Pharmaceuticals had a net margin of 17.87% and a trailing twelve-month return on equity of 17.35%. During the same period in the previous year, the firm earned $0.27 EPS. View Amphastar Pharmaceuticals' earnings history. Who are Amphastar Pharmaceuticals' key executives? Amphastar Pharmaceuticals' management team includes the following people: Dr. Ziping Luo Ph.D., Chairman, Chief Scientist & COO (Age 72, Pay $1.34M)Dr. Yongfeng Zhang Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 75, Pay $1.93M)Mr. William J. Peters M.B.A., CFO, Exec. VP of Fin. & Treasurer (Age 54, Pay $1.11M) (LinkedIn Profile)Mr. Jacob Liawatidewi M.B.A., Exec. VP of Sales, Marketing & Corp. Admin. Center and Corp. Sec. (Age 48, Pay $773.69k)Mr. Rong Zhou M.S., Exec. VP of Production Center (Age 63, Pay $842.77k) (LinkedIn Profile)Dan Dischner, VP of Corp. CommunicationsTony Marrs, Sr. VP of Regulatory Affairs and Clinical OperationsMr. Peter Langosh, VP of Operational Improvement and VP of Internal Audit (Age 69) What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO? 27 employees have rated Amphastar Pharmaceuticals CEO Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among Amphastar Pharmaceuticals' employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Amphastar Pharmaceuticals' key competitors? Some companies that are related to Amphastar Pharmaceuticals include Perrigo (PRGO), Intra-Cellular Therapies (ITCI), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Hypera (HYPMY), Ultragenyx Pharmaceutical (RARE), Cytokinetics (CYTK), Evotec (EVTCY), Cerevel Therapeutics (CERE), Turning Point Therapeutics (TPTX), Karuna Therapeutics (KRTX), Mirati Therapeutics (MRTX) and Arrowhead Pharmaceuticals (ARWR). View all of AMPH's competitors. What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT). What is Amphastar Pharmaceuticals' stock symbol? Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH." How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amphastar Pharmaceuticals' stock price today? One share of AMPH stock can currently be purchased for approximately $34.15. How much money does Amphastar Pharmaceuticals make? Amphastar Pharmaceuticals (NASDAQ:AMPH) has a market capitalization of $1.67 billion and generates $437.77 million in revenue each year. The company earns $62.12 million in net income (profit) each year or $1.61 on an earnings per share basis. How many employees does Amphastar Pharmaceuticals have? Amphastar Pharmaceuticals employs 1,761 workers across the globe. How can I contact Amphastar Pharmaceuticals? Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The official website for Amphastar Pharmaceuticals is www.amphastar.com. The company can be reached via phone at (909) 980-9484, via email at [email protected], or via fax at 909-980-8296. This page (NASDAQ:AMPH) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
